Article

Research Examines Cost Effective Method to Grow New Liver Cells from Stem Cells

Process may lead to better quality liver cells derived from clinical grade stem cells.

The difficulties of liver illness can stretch beyond just the impact on physical wellbeing, but can also become a significant cost burden on these patients.

However, researchers are currently working to develop new cost effective techniques for growing liver cells out of stem cells, for sufferers of liver damage.

In the past, the use of liver cells has shown some success in patient therapies, but donor organs are the only real source of cells.

Growing liver cells from stem cells show great promise, but the existing methods rely on animal products derived from tumors, which cannot be given to patients.

In a recent study, researchers developed a new process in which the cells use synthetic material of naturally occurring molecules called laminins instead of animal products, which was found to be much safer for humans.

The laminins act as a support, surrounding the cells and shaping the complex structures found in liver tissue. By growing stem cells on these laminins, it turned them into more efficient organized liver cells.

"The development of a defined process to deliver better quality liver cells from clinical grade stem cells is a significant advance,” said Dave Hay, MD, a scientists from the study. “The next step will be to assess their suitability for human use in the appropriate pre-clinical models."

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards